THE ARISING · Markets & Strategy
Alzheimer’s Pill Shows a Signal in One Prespecified Group, Not the Full Trial
AriBio reported a smaller decline with its experimental pill in a group without certain background Alzheimer’s medications. The full trial population showed no statistically significant difference.
The phase 3 POLARIS-AD trial randomized 1,535 people with early Alzheimer’s disease to AR1001 or placebo for 52 weeks. The trial measured change on a scale that combines cognition and daily function. It tested that same outcome in two prespecified populations, with a statistical rule that allowed the trial to meet its efficacy objective in either one.
In the full population, the difference versus placebo was −0.11 points and was not statistically significant. In the 604-person population not taking a cholinesterase inhibitor or memantine at baseline, AriBio reported a −0.44-point difference, or 31% less decline relative to placebo (p = .0266). That means slower worsening on the study scale, not an improvement from baseline. The company reported the findings at a conference; they do not establish benefit for the wider Alzheimer’s population or explain why the two results differed.
AriBio’s commercial partner Fosun reported diarrhea in 7.7% of patients receiving AR1001 versus 4.4% on placebo, and serious adverse events in 10.0% versus 9.8%. The drug remains investigational. The next test is a full review of the results, including whether the difference is large enough to matter in daily life and what regulators make of it.
A relative percentage gives only part of the picture. The absolute gap was less than half a point on the trial scale, and the sponsor did not show a significant difference when all participants were analyzed together. The finding raises a question for further work: does the treatment have a reproducibly different effect in people who start without those other medicines?
ClinicalTrials.gov: POLARIS-AD · AriBio topline results · Fosun disclosure